Matches in SemOpenAlex for { <https://semopenalex.org/work/W3123696223> ?p ?o ?g. }
- W3123696223 endingPage "108679" @default.
- W3123696223 startingPage "108679" @default.
- W3123696223 abstract "HER2-targeted therapy has not benefited patients with low levels of HER2 expression; however, combination therapy may be effective. Primary analysis of a phase IIb trial investigating the HER2-derived vaccine nelipepimut-S (NPS) did not benefit the intention-to-treat population, but subset analysis showed a benefit in triple-negative breast cancer (TNBC) patients. The subset analysis of this multicenter, randomized, single-blind, phase IIb trial identified significant improvement in 36-month disease-free survival (DFS) between NPS (n = 55) and placebo (n = 44) in TNBC (HR 0.25, p = 0.01) and those who express HLA-A24 (HR 0.41, p = 0.05). The TNBC cohort demonstrated improved 36-month DFS in those with HER2 1+ expression (HR 0.17, p = 0.01), HLA-A24 positivity (HR 0.08, p < 0.01), or in those who received neoadjuvant chemotherapy (HR 0.21, p < 0.01). NPS vaccination with trastuzumab was associated with improved 36-month DFS among patients with TNBC. The observed benefit to this high-risk subgroup warrants confirmation in a phase III trial." @default.
- W3123696223 created "2021-02-01" @default.
- W3123696223 creator A5003244604 @default.
- W3123696223 creator A5014713051 @default.
- W3123696223 creator A5018907752 @default.
- W3123696223 creator A5024700109 @default.
- W3123696223 creator A5027659488 @default.
- W3123696223 creator A5027764647 @default.
- W3123696223 creator A5029062544 @default.
- W3123696223 creator A5029855695 @default.
- W3123696223 creator A5035547335 @default.
- W3123696223 creator A5044161354 @default.
- W3123696223 creator A5050537038 @default.
- W3123696223 creator A5065391640 @default.
- W3123696223 creator A5068315925 @default.
- W3123696223 creator A5073826514 @default.
- W3123696223 creator A5078106693 @default.
- W3123696223 creator A5078173980 @default.
- W3123696223 date "2021-04-01" @default.
- W3123696223 modified "2023-10-16" @default.
- W3123696223 title "Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer" @default.
- W3123696223 cites W1530219086 @default.
- W3123696223 cites W1916710129 @default.
- W3123696223 cites W1991228426 @default.
- W3123696223 cites W1999286297 @default.
- W3123696223 cites W2023685040 @default.
- W3123696223 cites W2088206187 @default.
- W3123696223 cites W2107413762 @default.
- W3123696223 cites W2110250476 @default.
- W3123696223 cites W2152811375 @default.
- W3123696223 cites W2339726760 @default.
- W3123696223 cites W2466558384 @default.
- W3123696223 cites W2619908690 @default.
- W3123696223 cites W2737898225 @default.
- W3123696223 cites W2745792339 @default.
- W3123696223 cites W2762153201 @default.
- W3123696223 cites W2778092352 @default.
- W3123696223 cites W2897422388 @default.
- W3123696223 cites W2898389621 @default.
- W3123696223 cites W2900898778 @default.
- W3123696223 cites W2909799373 @default.
- W3123696223 cites W2915498065 @default.
- W3123696223 cites W2923651250 @default.
- W3123696223 cites W2937981811 @default.
- W3123696223 cites W2982449517 @default.
- W3123696223 cites W2994917610 @default.
- W3123696223 cites W3004453915 @default.
- W3123696223 cites W3005738019 @default.
- W3123696223 cites W3006455065 @default.
- W3123696223 cites W3007421866 @default.
- W3123696223 cites W4232529261 @default.
- W3123696223 cites W4361867966 @default.
- W3123696223 doi "https://doi.org/10.1016/j.clim.2021.108679" @default.
- W3123696223 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33485895" @default.
- W3123696223 hasPublicationYear "2021" @default.
- W3123696223 type Work @default.
- W3123696223 sameAs 3123696223 @default.
- W3123696223 citedByCount "16" @default.
- W3123696223 countsByYear W31236962232021 @default.
- W3123696223 countsByYear W31236962232022 @default.
- W3123696223 countsByYear W31236962232023 @default.
- W3123696223 crossrefType "journal-article" @default.
- W3123696223 hasAuthorship W3123696223A5003244604 @default.
- W3123696223 hasAuthorship W3123696223A5014713051 @default.
- W3123696223 hasAuthorship W3123696223A5018907752 @default.
- W3123696223 hasAuthorship W3123696223A5024700109 @default.
- W3123696223 hasAuthorship W3123696223A5027659488 @default.
- W3123696223 hasAuthorship W3123696223A5027764647 @default.
- W3123696223 hasAuthorship W3123696223A5029062544 @default.
- W3123696223 hasAuthorship W3123696223A5029855695 @default.
- W3123696223 hasAuthorship W3123696223A5035547335 @default.
- W3123696223 hasAuthorship W3123696223A5044161354 @default.
- W3123696223 hasAuthorship W3123696223A5050537038 @default.
- W3123696223 hasAuthorship W3123696223A5065391640 @default.
- W3123696223 hasAuthorship W3123696223A5068315925 @default.
- W3123696223 hasAuthorship W3123696223A5073826514 @default.
- W3123696223 hasAuthorship W3123696223A5078106693 @default.
- W3123696223 hasAuthorship W3123696223A5078173980 @default.
- W3123696223 hasConcept C121608353 @default.
- W3123696223 hasConcept C126322002 @default.
- W3123696223 hasConcept C142724271 @default.
- W3123696223 hasConcept C143998085 @default.
- W3123696223 hasConcept C187960798 @default.
- W3123696223 hasConcept C204787440 @default.
- W3123696223 hasConcept C27081682 @default.
- W3123696223 hasConcept C2776694085 @default.
- W3123696223 hasConcept C2779786085 @default.
- W3123696223 hasConcept C2908647359 @default.
- W3123696223 hasConcept C44249647 @default.
- W3123696223 hasConcept C530470458 @default.
- W3123696223 hasConcept C71924100 @default.
- W3123696223 hasConcept C72563966 @default.
- W3123696223 hasConcept C90924648 @default.
- W3123696223 hasConcept C99454951 @default.
- W3123696223 hasConceptScore W3123696223C121608353 @default.
- W3123696223 hasConceptScore W3123696223C126322002 @default.
- W3123696223 hasConceptScore W3123696223C142724271 @default.
- W3123696223 hasConceptScore W3123696223C143998085 @default.